DAVID GRANOVSKY

Stem cell production deal boosts Brainstorm’s share

In BUSINESS OF STEM CELLS on September 6, 2009 at 11:47 am

The move brings Brainstorm a step closer to a clinical trial for its ALS product.

Gali Weinreb6 Sep 09 12:52

Despite falling 30% on Thursday and Friday, Brainstorm Cell Therapeutics Ltd. (Bulletin Board:BCLI.OB), a developer of adult stem cell technologies and therapeutics for neurodegenerative diseases, still saw its share rise 60% over last week after reporting a production deal. The share closed at $0.24 on Friday, giving a market cap of $14.35 million.

Brainstorm said that it had agreed to start production with Protein Production Services Ltd. (PPS), a manufacturing contractor. The clinical-grade product will be used in a pre-clinical safety trial for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

via Stem cell production deal boosts Brainstorm’s share.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: